1251570-88-3

Basic information

• Product Name: (S)-tert-butyl 3-((S)-1-hydroxy-3-methylbutyl)pyrrolidine-1-carboxylate
• Synonyms: (S)-tert-butyl 3-((S)-1-hydroxy-3-methylbutyl)pyrrolidine-1-carboxylate;(S)-tert-butyl 3-((S)-1-hydroxy-3-Methylbutyl)pyrrolidine-1-carb
• CAS NO: 1251570-88-3
• Molecular Formula: C₁₄H₂₇NO₃
• Molecular Weight: 257
• Mol File: 1251570-88-3.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (S)-tert-butyl 3-((S)-1-hydroxy-3-methylbutyl)pyrrolidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-tert-butyl 3-((S)-1-hydroxy-3-methylbutyl)pyrrolidine-1-carboxylate(1251570-88-3)
• EPA Substance Registry System: (S)-tert-butyl 3-((S)-1-hydroxy-3-methylbutyl)pyrrolidine-1-carboxylate(1251570-88-3)

Safety Data

• Hazardous Substances Data: 1251570-88-3(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(S)-tert-butyl 3-((S)-1-hydroxy-3-methylbutyl)pyrrolidine-1-carboxylate is used as a reagent in organic synthesis for its unique structural features, including the tert-butyl group and the chiral center, which can be leveraged to create a variety of complex organic molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (S)-tert-butyl 3-((S)-1-hydroxy-3-methylbutyl)pyrrolidine-1-carboxylate is used as a key intermediate in the development of new drugs. Its chiral nature allows for the synthesis of enantiomerically pure compounds, which is essential for ensuring the desired biological activity and minimizing potential side effects.
Used in Chiral Compound Preparation:
(S)-tert-butyl 3-((S)-1-hydroxy-3-methylbutyl)pyrrolidine-1-carboxylate is utilized in the preparation of chiral compounds, which are important in various chemical and biological processes. (S)-tert-butyl 3-((S)-1-hydroxy-3-methylbutyl)pyrrolidine-1-carboxylate's stereochemistry plays a critical role in determining the effectiveness and selectivity of these compounds in their applications.
Used in Drug Development:
In drug development, (S)-tert-butyl 3-((S)-1-hydroxy-3-methylbutyl)pyrrolidine-1-carboxylate is used as a building block for the creation of novel pharmaceuticals. Its unique structure and chirality make it a valuable component in the design and synthesis of new therapeutic agents with improved efficacy and selectivity.

Upstream product

• 122684-33-7 methyl 1-tert-butoxycarbonyl-3-pyrrolidinecarboxylate 
• 313706-15-9 O⁽¹⁾-tert-butyl O⁽³⁾-methyl (3S)-pyrrolidine-1,3-dicarboxylate 
• 140148-70-5 (S)-1-N-boc-β-proline 
• 1204677-53-1 tert-butyl (3S)-3-(methoxy(methyl)carbamoyl)pyrrolidine-1-carboxylate 
• 1251570-77-0 tert-butyl (3S)-3-(3-methylbutanoyl)pyrrolidine-1-carboxylate 
• 117175-36-7 (S)-2-(benzyloxy)-4-methylpentan-1-ol 
• 144491-18-9 (S)-2-benzyloxy-4-methylpentanal 
• 5674-02-2 2-methylpropylmagnesium chloride 
• 191348-04-6 (S)-3-formylpyrrolidine-1-carboxylic acid t-butyl ester 

Relevant articles and documents

An enantioselective approach to 3-substituted pyrrolidines: Asymmetric synthesis for pyrrolidine core of serotonin norepinephrine reuptake inhibitors (SNRIs)

A novel and efficient synthetic approach to enantiopure 3-substituted pyrrolidine skeleton from readily available (S)-PMB glycidyl ether as a starting material and its application to the asymmetric synthesis of pyrrolidine core 1 of serotonin norepinephrine reuptake inhibitors (SNRIs) 2 and 3 are described. The synthesis utilizes the organocatalyzed asymmetric Michael addition reaction as key step.

Discovery of a potent, dual serotonin and norepinephrine reuptake inhibitor

The objective of the described research effort was to identify a novel serotonin and norepinephrine reuptake inhibitor (SNRI) with improved norepinephrine transporter activity and acceptable metabolic stability and exhibiting minimal drug-drug interaction. We describe herein the discovery of a series of 3-substituted pyrrolidines, exemplified by compound 1. Compound 1 is a selective SNRI in vitro and in vivo, has favorable ADME properties, and retains inhibitory activity in the formalin model of pain behavior. Compound 1 thus represents a potential new probe to explore utility of SNRIs in central nervous system disorders, including chronic pain conditions.

3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS

In one aspect, the invention relates to compounds of formula I: where R1-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. In a

SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR

A serotonin and norepinephrine reuptake inhibitor of the formula: its uses, and methods for its preparation are described.